This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gulamhusein, S. Articles by Klein, G. J. Search for Related Content PubMed PubMed Citation Articles by Gulamhusein, S. Articles by Klein, G. J.

Circulation, Vol 65, 348-354, Copyright © 1982 by American Heart Association

ARTICLES

Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil

S Gulamhusein, P Ko, SG Carruthers and GJ Klein

We examined the electrophysiologic effects of verapamil in eight patients with the Wolff-Parkinson-White syndrome. Verapamil shortened the antegrade effective refractory period of the accessory pathway in three patients and abbreviated the shortest cycle length with 1:1 conduction over the accessory pathway in two patients. More significantly, verapamil decreased the shortest RR interval between preexcited ventricular complexes during atrial fibrillation (279 +/- 20 msec vs 236 +/- 18 msec, mean +/- SEM; p less than 0.01). After verapamil, two patients required cardioversion for hemodynamic deterioration after acceleration of the ventricular response during atrial fibrillation. In the four patients with predominantly preexcited ventricular complexes during atrial fibrillation the ventricular rate accelerated after verapamil, whereas in patients with predominantly normal ventricular complexes, the average ventricular rate decreased or did not change after verapamil. Verapamil may result in significant acceleration of ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome. The safety of verapamil in individual patients with the Wolff-Parkinson-White syndrome should be established by electrophysiologic testing before its use.

This article has been cited by other articles:

				L. I. Ganz and P. L. Friedman Supraventricular Tachycardia N. Engl. J. Med., January 19, 1995; 332(3): 162 - 173. [Full Text] [PDF]

				A. S. Manolis and N. A. M. Estes III Supraventricular Tachycardia: Mechanisms and Therapy Arch Intern Med, October 1, 1987; 147(10): 1706 - 1716. [Abstract] [PDF]

				E. N. SHEN, E. KEUNG, E. HUYCKE, M. L. DOHRMANN, N. NGUYEN, F. MORADY, and R. J. SUNG Intravenous Propafenone for Termination of Reentrant Supraventricular Tachycardia: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study Ann Intern Med, November 1, 1986; 105(5): 655 - 661. [Abstract] [PDF]

				R. B. STEWART, G. H. BARDY, and H. L. GREENE Wide Complex Tachycardia: Misdiagnosis and Outcome After Emergent Therapy Ann Intern Med, June 1, 1986; 104(6): 766 - 771. [Abstract] [PDF]

				B. McGOVERN, H. GARAN, and J. N. RUSKIN Precipitation of Cardiac Arrest by Verapamil in Patients with Wolff-ParkinsonWhite Syndrome Ann Intern Med, June 1, 1986; 104(6): 791 - 794. [Abstract] [PDF]

				R. Ruffy, M. Sears, and L. V. Avioli Wolff-Parkinson-White Syndrome Arch Intern Med, March 1, 1985; 145(3): 533 - 536. [Abstract] [PDF]

				J. M. Richardson Ventricular Preexcitation-Reply Arch Intern Med, November 1, 1983; 143(11): 2218 - 2218. [Abstract] [PDF]

				G. R. Hasegawa Ventricular Preexcitation Arch Intern Med, November 1, 1983; 143(11): 2215 - 2218. [Abstract] [PDF]